...
首页> 外文期刊>Systematic Reviews >Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus
【24h】

Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus

机译:MOMORDICA Charantia L.患有2型糖尿病的动物模型的系统评价和荟萃分析议定书

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Studies on several preclinical models of type 2 diabetes mellitus have been conducted to establish the hypoglycemic activity of Momordica charantia L. Concerned with appropriateness of these models, we designed a systematic review to establish the efficacy and safety of M. charantia L. in preclinical models of type 2 diabetes mellitus. Review authors will search without language restriction in MEDLINE/PubMed, Web of Science, Embase, Scopus, and CINAHL databases through April 2019. Search filters will be applied to enhance search efficiency. The authors will search for gray literature in Google and Google Scholar, OpenGrey, and ProQuest Dissertations & Theses. Two authors will evaluate full texts, extract data, and asses risk of bias independently. The review will include randomized or non-randomized studies that assessed the efficacy or safety of M. charantia L. with vehicle control group. The primary endpoint will be fasting blood glucose level. We will use Egger’s test to assess publication biases. Chi-square test and I2 will be used to assess heterogeneity in effect size of the primary outcome. Using RevMan software version 5.3, the authors will perform a meta-analysis of quantitative data. The strength of evidence will be rated as high, moderate, low, or very low using GRADE framework for animal studies. This systematic review will potentially improve research practice by identifying risks of bias and design features that compromise translatability and contribute to evidence-based clinical trial design.
机译:对2型糖尿病型态度牙髓炎型临床前模型的研究已经进行了,以确定苦瓜的低血糖活性,涉及这些模型的适当性,我们设计了一个系统的审查,以确定M. Charantia L.在临床前模型中的疗效和安全性2型糖尿病。回顾作者将在2019年4月在Medline / PubMed,Science,Scase,Scopus和Cinahl数据库中没有语言限制。搜索过滤器将应用于提高搜索效率。作者将在Google和Google Scholar,OpenGrey和Proquest论文和论文中搜索灰色文学。两位作者将评估全文,提取数据,并独立偏见的风险。审查将包括随机或非随机性研究,评估M. Charantia L.与载体对照组的疗效或安全性。主要终点将是空腹血糖水平。我们将使用Egger的测试来评估出版物偏见。 Chi-Square测试和I2将用于评估主要结果的效果大小的异质性。使用Revman Software 5.3版,作者将对定量数据进行META分析。证据强度将被评为高,中等,低,低或非常低,使用等级的动物研究框架。这种系统审查将通过识别损害易化性的偏差和设计特征的风险以及促进基于证据的临床试验设计的风险来潜在地改善研究实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号